Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
Kartik Sehgal, Daniel B. Costa, Deepa Rangachari
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 18

Showing 18 citing articles:

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
Vincenzo Quagliariello, Margherita Passariello, Annabella Di Mauro, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 31
Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
Mengjie Jiang, Yujie Hu, Gang Lin, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 28
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
Austin Wesevich, Daniel A. Goldstein, Koosha Paydary, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 9, pp. 1389-1396
Closed Access | Times Cited: 10
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
Benjamin Switzer, John B.A.G. Haanen, Paul Lorigan, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002835-e002835
Open Access | Times Cited: 16
Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis
L Gilbert, Refael Alfa Budiman, Ikhwan Rinaldi
Cancer Immunology Immunotherapy (2021) Vol. 71, Iss. 2, pp. 373-386
Open Access | Times Cited: 14
Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group
Nam P. Nguyen, Brigitta G. Baumert, Eromosele Oboite, et al.
Gerontology (2021) Vol. 67, Iss. 4, pp. 379-385
Open Access | Times Cited: 12
Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics
Shujun Dong, Ian Nessler, Anna Kopp, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 7
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation
Stephanie N. Liu, Mathilde Marchand, Xiaoyan Liu, et al.
The Journal of Clinical Pharmacology (2022) Vol. 62, Iss. 11, pp. 1393-1402
Closed Access | Times Cited: 6
Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors
Zafer Gürel, Michael S Luy, Qianyun Luo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study
Graham Cohen, Bernardo L. Rapoport, Sze Wai Chan, et al.
PLoS ONE (2024) Vol. 19, Iss. 11, pp. e0309778-e0309778
Open Access
An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic
Gordon Taylor Moffat, Lilian Hanna, Wilma M. Hopman, et al.
Immunotherapy (2023) Vol. 15, Iss. 12, pp. 921-932
Open Access | Times Cited: 1
Coronavirus disease 2019 and lung cancer: where are we?
Abrahams Ocanto, Xabier Mielgo-Rubio, J. Luna, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 1082-1094
Open Access | Times Cited: 1
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study
Julien Colard‐Thomas, C. Manceron, Claire Duflos, et al.
ESMO Open (2023) Vol. 8, Iss. 6, pp. 102070-102070
Open Access | Times Cited: 1
In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
Irena Wieleba, Kamila Wojas‐Krawczyk, Izabela Chmielewska, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Nivolumab in two cases of refractory mycosis fungoides erythroderma
Ewa Chmielowska
Central European Journal of Immunology (2021) Vol. 46, Iss. 4, pp. 535-538
Open Access | Times Cited: 2
Immune checkpoint inhibitor does not increase risks of poor outcomes in cancer patients with COVID-19 infection: A systematic review and meta-analysis
L Gilbert, Refael Alfa Budiman, Ikhwan Rinaldi
Research Square (Research Square) (2020)
Closed Access | Times Cited: 1
The effect of the earliest COVID-19 outbreak on survival in uninfected advanced NSCLC patients receiving chemotherapy in Jiangsu Province, China: A retrospective cohort study
Heng Lu, Yue Wang, Guoqiang Feng, et al.
Medicine (2023) Vol. 102, Iss. 39, pp. e34559-e34559
Open Access
Direct and indirect impacts of the COVID-19 pandemic on patients with pulmonary and pleural malignancies – a retrospective analysis of patient outcomes treated at Department of Respiratory Diseases, University Hospital Brno, during the 2nd and 3rd coronavirus waves
Monika Bratová, Kristián Brat, Lenka Jakubíková
Klinicka onkologie (2022) Vol. 35, Iss. 3
Open Access
Page 1

Scroll to top